



CofC

PATENT  
ATTORNEY DOCKET NO. 00742/056003

Certificate of Mailing: Date of Deposit: 1/11/06

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Attention: Certificate of Correction Branch.

Antonio J. Freitas  
Printed name of person mailing correspondence

Antonio J. Freitas  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Junying Yuan et al.

Art Unit: 1626

Serial No.: 09/688,015

Examiner: A. Small

Filed: October 13, 2000

Customer No.: 21559

Patent No.: 6,756,394 B1

Issued: June 29, 2004

Title: SMALL MOLECULE INHIBITORS OF NECROSIS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Attention: Certificate of Correction Branch

**Certificate**  
**JAN 19 2006**  
**of Correction**

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322


Applicants hereby requests that a Certificate of Correction be issued in the patent identified above. The error to be corrected is described in detail on the enclosed PTO Form 1050. Applicants note that the references cited on the enclosed PTO Form 1449 were initialed by the Examiner but are not included in the patent identified above.

JAN 19 2006

No fee is believed to be due, as the error to be corrected was made by the PTO. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: January 11, 2006

  
Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. 6,756,394 *β1*  
DATED June 29, 2004  
INVENTORS Yuan et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the cover sheet, in "References Cited", in "Other Publications", insert --Borner et al., "Apoptosis Without Caspases: An Inefficient Molecular Guillotine?," *Cell Death Differ.* 6:497-507 (1999).  
Búyúkbingöl et al., "Studies on the Synthesis and Structure-Activity Relationships of 5-(3'-Indolal)-2-Thiohydantoin Derivatives as Aldose Reductase Enzyme Inhibitors," *Farmaco* 49:443-447 (1994).  
Chi et al., "Oncogenic Ras Triggers Cell Suicide Through the Activation of a Caspase-Independent Cell Death Program in Human Cancer Cells," *Oncogene* 18:2281-2290 (1999).  
Fiers et al., "More Than One Way to Die: Apoptosis, Necrosis and Reactive Oxygen Damage," *Oncogene* 18:7719-7730 (1999).  
Herceg et al., "Failure of Poly(ADP-Ribose) Polymerase Cleavage by Caspases Leads to Induction of Necrosis and Enhanced Apoptosis," *Mol. Cell. Biol.* 19:5124-5133 (1999).  
Hirsch et al., "The Apoptosis-Necrosis Paradox. Apoptogenic Proteases Activated After Mitochondrial Permeability Transition Determine the Mode of Cell Death," *Oncogene* 15:1573-1581 (1997).  
Holler et al., "Fas Triggers an Alternative, Caspase-8-Independent Cell Death Pathway Using the Kinase RIP as Effector Molecule," *Nature Immunol.* 1:489-495 (2000).  
Kawahara et al., "Caspase-Independent Cell Killing by Fas-Associated Protein with Death Domain," *J. Cell Biol.* 143:1353-1360 (1998).  
Khwaja et al., "Resistance to the Cytotoxic Effects of Tumor Necrosis Factor Alpha can be Overcome by Inhibition of a FADD/Caspase-Dependent Signaling Pathway," *J. Biol. Chem.* 274:36817-36823 (1999).  
Kitanaka et al., "Caspase-Independent Programmed Cell Death with Necrotic Morphology," *Cell Death Differ.* 6:508-515 (1999).  
Leist et al., "Inhibition of Mitochondrial ATP Generation by Nitric Oxide Switches Apoptosis to Necrosis," *Exp. Cell Res.* 249:396-403 (1999). --

(Correction continued on next sheet)

MAILING ADDRESS OF SENDER:

Kristina Bieker-Brady, Ph.D.  
Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Customer No.: 21559

SUBSTITUTE FORM PTO 1050

PATENT NO. 6,756,394

NO. ADDITIONAL COPIES  
@ 50¢ PER PAGE

JAN 19 2006

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. 6,756,394 *β1*  
DATED June 29, 2004  
INVENTORS Yuan et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(Continued from previous sheet)

On the cover sheet, in "References Cited", in "Other Publications", insert --Li et al., "Induction of Necrotic-Like Cell Death by Tumor Necrosis Factor Alpha and Caspase Inhibitors: Novel Mechanism for Killing Virus-Infected Cells," *J. Virol.* 74:7470-7477 (2000).  
Lüschen et al., "Sensitization to Death Receptor Cytotoxicity by Inhibition of Fas-Associated Death Domain Protein (FADD)/Caspase Signaling. Requirement of Cell Cycle Progression," *J. Biol. Chem.* 275:24670-24678 (2000).  
Matsumura et al., "Necrotic Death Pathway in Fas Receptor Signaling," *J. Cell Biol.* 151:1247-1255 (2000).  
McCarthy et al., "Inhibition of Ced-3/ICE-Related Proteases does not Prevent Cell Death Induced by Oncogenes, DNA Damage, or the Bcl-2 Homologue Bak," *J. Cell Biol.* 136:215-227 (1997).  
Sané et al., "Caspase Inhibition in Camptothecin-Treated U-937 Cells is Coupled with a Shift from Apoptosis to Transient G<sub>0</sub> Arrest Followed by Necrotic Cell Death," *Cancer Res.* 59:3565-3569 (1999).  
Vercammen et al., "Inhibition of Caspases Increases the Sensitivity of L929 Cells to Necrosis Mediated by Tumor Necrosis Factor," *J. Exp. Med.* 187:1477-1485 (1998).  
Vercammen et al., "Dual Signaling of the Fas Receptor: Initiation of Both Apoptotic and Necrotic Cell Death Pathways," *J. Exp. Med.* 188:919-930 (1998).--

Column 10, Line 36, replace "in co a" with --in a--.

Column 21, Line 53, replace "chemical" with --chemical compound--.

MAILING ADDRESS OF SENDER:

Kristina Bieker-Brady, Ph.D.  
Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Customer No.: 21559

SUBSTITUTE FORM PTO 1050

PATENT NO. 6,756,394

NO. ADDITIONAL COPIES  
@ 50¢ PER PAGE

JAN 19 2006

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. 6,756,394 *Bl*  
DATED June 29, 2004  
INVENTORS Yuan et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 23,

Line 44, replace "methoxyl," with --methoxyl, amino,--; and  
Line 47, replace "acyl," with --acyl, halogen,--.

Column 24, Line 36, replace "alyl" with --alkyl--.

MAILING ADDRESS OF SENDER:

Kristina Bieker-Brady, Ph.D.  
Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Customer No.: 21559

SUBSTITUTE FORM PTO 1050


PATENT NO. 6,756,394  
NO. ADDITIONAL COPIES  
@ 50¢ PER PAGE

JAN 19 2006

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Attorney Docket No. 00742/056003  
 Serial No. 09/688,015  
 Applicant Junying Yuan et al.  
 Filing Date October 13, 2000  
 Group 1614  
 IDS Filed March 9, 2001  
 Customer No. 21559

(37 CFR §1.98(b))



U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

AMD	Borner et al., "Apoptosis without caspases: an inefficient molecular guillotine?," <i>Cell Death Differ.</i> 6:497-507 (1999). -
AMD	Büyükbingöl et al., "Studies on the synthesis and structure-activity relationships of 5-(3'-indolyl)-2-thiohydantoin derivatives as aldose reductase enzyme inhibitors," <i>Il Farmaco</i> 49:443-447 (1994).
AMD	Chi et al., "Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells," <i>Oncogene</i> 18:2281-2290 (1999).
AMD	Fiers et al., "More than one way to die: apoptosis, necrosis and reactive oxygen damage," <i>Oncogene</i> 18:7719-7730 (1999).
AMD	Herceg et al., "Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis," <i>Mol. Cell Biol.</i> 19:5124-5133 (1999).
AMD	Hirsch et al., "The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death," <i>Oncogene</i> 15:1573-1581 (1997).
AMD	Holler et al., "Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule," <i>Nature Immunol.</i> 1:489-495 (2000).
AMD	Kawahara et al., "Caspase-independent cell killing by Fas-associated protein with death domain," <i>J. Cell Biol.</i> 143:1353-1360 (1998).
AMD	Khwaja et al., "Resistance to the cytotoxic effects of tumor necrosis factor alpha can be overcome by inhibition of a FADD/caspase-dependent signaling pathway," <i>J. Biol. Chem.</i> 274:36817-36823 (1999).
AMD	Kitanaka et al., "Caspase-independent programmed cell death with necrotic morphology," <i>Cell Death Differ.</i> 6:508-515 (1999).

EXAMINER

DATE CONSIDERED 5/24/01

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

RECEIVED  
MAR 15 2001  
PTO CENTER 1600/2900

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		Attorney Docket No. 00742/056003
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 09/688,015
(37 CFR §1.98(b))		Applicant Junying Yuan et al.
		Filing Date October 13, 2000
		Group 1614
		IDS Filed March 9, 2001
		Customer No. 21559



## U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

AMD	Leist et al., "Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis," <i>Exp. Cell Res.</i> 249:396-403 (1999).
AMD	Li et al., "Induction of necrotic-like cell death by tumor necrosis factor alpha and caspase inhibitors: Novel mechanism for killing virus-infected cells," <i>J. Virol.</i> 74:7470-7477 (2000).
AMD	Löschner et al., "Sensitization to death receptor cytotoxicity by inhibition of fas-associated death domain protein (FADD)/caspase signaling. Requirement of cell cycle progression," <i>J. Biol. Chem.</i> 275:24670-24678 (2000).
AMD	Matsumura et al., "Necrotic death pathway in Fas receptor signaling," <i>J. Cell Biol.</i> 151:1247-1255 (2000).
AMD	McCarthy et al., "Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak," <i>J. Cell Biol.</i> 136:215-227 (1997).
AMD	Sané et al., "Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G <sub>1</sub> arrest followed by necrotic cell death," <i>Cancer Res.</i> 59:3565-3569 (1999).
AMD	Vercammen et al., "Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor," <i>J. Exp. Med.</i> 187:1477-1485 (1998).
AMD	Vercammen et al., "Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic cell death pathways," <i>J. Exp. Med.</i> 188:919-930 (1998).

EXAMINER <i>[Signature]</i>	DATE CONSIDERED 5/24/01
-----------------------------	-------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

RECEIVED  
MAR 15 2001  
EPO CENTER 1600/2900